{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T22:25:49Z","timestamp":1786919149612,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Municipal Science and Technology Project","award":["25ZR1401066"],"award-info":[{"award-number":["25ZR1401066"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acquired therapy resistance, particularly endocrine resistance in estrogen receptor-positive (ER\u2009+) breast cancer, remains a major clinical challenge. Proteolysis-targeting chimeras (PROTACs) have emerged as a novel therapeutic paradigm with the potential to overcome resistance by degrading target proteins. This study provides a comprehensive landscape analysis of PROTACs in breast cancer, synthesizing research trends and clinical trial progress to map the path from discovery to application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a dual-perspective analysis. Bibliometric data from 350 publications (Web of Science Core Collection) were analyzed to delineate the research evolution, collaboration networks, and target focus. Concurrently, 30 clinical trials registered on ClinicalTrials.gov were systematically reviewed to evaluate the clinical translational stage, target distribution, and safety profiles of PROTACs in breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Research output has grown exponentially since 2016, led by China and the United States. The estrogen receptor (ER) is the predominant target in both basic and clinical research. Clinical development is advancing rapidly, with the ER degrader ARV-471 reaching phase III trials. In patients with ER\u2009+\u2009\/HER2\u2009\u2212\u2009advanced breast cancer and ESR1 mutations, ARV-471 demonstrated a median progression-free survival of 5.0\u00a0months, doubling that achieved with fulvestrant (2.1\u00a0months). While fatigue and nausea are common adverse events, the overall safety profile appears manageable. However, clinical exploration remains highly concentrated on ER\u2009+\u2009disease, with limited progress in other subtypes such as HER2\u2009+\u2009and triple-negative breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PROTACs, especially ER degraders, suggest a potential strategy for addressing endocrine resistance in advanced ER\u2009+\u2009breast cancer, as reflected in encouraging preliminary clinical data. This integrated analysis highlights the rapid translation of this technology while underscoring the critical need to expand target scope, address inherent resistance mechanisms, and broaden applications to other breast cancer subtypes. Our article synthesizes current knowledge and trial landscape, thereby providing a consolidated foundation to inform future research and clinical development of PROTACs in breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-026-02320-w","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:35:07Z","timestamp":1781008507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting drug resistance in breast cancer: a dual-perspective landscape analysis of PROTACs from bench to bedside"],"prefix":"10.1186","volume":"28","author":[{"given":"Yinlong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"3","key":"2320_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrc744","volume":"2","author":"BH Lerner","year":"2002","unstructured":"Lerner BH. Breast cancer activism: past lessons, future directions. Nat Rev Cancer. 2002;2(3):225\u201330.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2320_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288.","journal-title":"JAMA"},{"key":"2320_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108800","volume":"114","author":"X Ji","year":"2019","unstructured":"Ji X, Lu Y, Tian H, Meng X, Wei M, Cho WC. Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019;114:108800.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"2320_CR4","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.7150\/ijbs.109803","volume":"21","author":"Z Niu","year":"2025","unstructured":"Niu Z, He J, Wang S, Xue B, Zhang H, Hou R, et al. Targeting glycolysis for treatment of breast cancer resistance: current progress and future prospects. Int J Biol Sci. 2025;21(6):2589\u2013605.","journal-title":"Int J Biol Sci"},{"issue":"9","key":"2320_CR5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/nchembio.1887","volume":"11","author":"RJ Deshaies","year":"2015","unstructured":"Deshaies RJ. Prime time for PROTACs. Nat Chem Biol. 2015;11(9):634\u20135.","journal-title":"Nat Chem Biol"},{"issue":"15","key":"2320_CR6","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: Chimeric molecules that target proteins to the Skp1\u2013cullin\u2013F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA. 2001;98(15):8554\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2320_CR7","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.1021\/acs.jmedchem.2c02032","volume":"66","author":"B Xie","year":"2023","unstructured":"Xie B, Yin Z, Hu Z, Lv J, Du C, Deng X, et al. Discovery of a novel class of protacs as potent and selective estrogen receptor \u03b1 degraders to overcome endocrine-resistant breast cancer in vitro and in vivo. J Med Chem. 2023;66(10):6631\u201351.","journal-title":"J Med Chem"},{"issue":"1","key":"2320_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s42003-025-08013-y","volume":"8","author":"GL Morgan","year":"2025","unstructured":"Morgan GL, Dickson H, Ford B, et al. Pioneering protein degradation for agricultural applications. Commun Biol. 2025;8(1):591.","journal-title":"Commun Biol"},{"key":"2320_CR9","first-page":"724","volume":"2005","author":"MB Synnestvedt","year":"2005","unstructured":"Synnestvedt MB, Chen C, Holmes JH. CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annu Symp Proc. 2005;2005:724\u20138.","journal-title":"AMIA Annu Symp Proc"},{"issue":"7548","key":"2320_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/520429a","volume":"520","author":"D Hicks","year":"2015","unstructured":"Hicks D, Wouters P, Waltman L, De Rijcke S, Rafols I. Bibliometrics: the leiden manifesto for research metrics. Nature. 2015;520(7548):429\u201331.","journal-title":"Nature"},{"issue":"6","key":"2320_CR11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2505725","volume":"393","author":"M Campone","year":"2025","unstructured":"Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med. 2025;393(6):556\u201368.","journal-title":"N Engl J Med"},{"issue":"5","key":"2320_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.tips.2023.03.003","volume":"44","author":"Y Fang","year":"2023","unstructured":"Fang Y, Wang S, Han S, Zhao Y, Yu C, Liu H, et al. Targeted protein degrader development for cancer: Advances, challenges, and opportunities. Trends Pharmacol Sci. 2023;44(5):303\u201317.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"2320_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s11523-025-01175-z","volume":"20","author":"RS Finn","year":"2025","unstructured":"Finn RS, Rugo HS, Cortes J, et al. A decade after approval of the first CDK4\/6 inhibitor: a look back at Palbociclib\u2019s journey from discovery to approval and what\u2019s next in CDK inhibition in breast cancer. Target Oncol. 2025;20(6):917\u201336.","journal-title":"Target Oncol"},{"issue":"28","key":"2320_CR14","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40(28):3246\u201356.","journal-title":"J Clin Oncol"},{"issue":"24","key":"2320_CR15","doi-asserted-by":"publisher","first-page":"6259","DOI":"10.1158\/0008-5472.CAN-21-1256","volume":"81","author":"X Gou","year":"2021","unstructured":"Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, et al. Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer. Cancer Res. 2021;81(24):6259\u201372.","journal-title":"Cancer Res"},{"key":"2320_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102387","volume":"56","author":"Z Lu","year":"2025","unstructured":"Lu Z, Wang T, Wang L, Ming J. Research progress on estrogen receptor-positive\/progesterone receptor-negative breast cancer. Transl Oncol. 2025;56:102387.","journal-title":"Transl Oncol"},{"issue":"12","key":"2320_CR17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","volume":"18","author":"M Schapira","year":"2019","unstructured":"Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discov. 2019;18(12):949\u201363.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2320_CR18","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.1038\/s41467-023-42233-2","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang J, Wang T, et al. Expanding PROTACtable genome universe of E3 ligases. Nat Commun. 2023;14(1):6509.","journal-title":"Nat Commun"},{"issue":"1","key":"2320_CR19","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1038\/s41467-025-62099-w","volume":"16","author":"K Baek","year":"2025","unstructured":"Baek K, Metivier RJ, Roy Burman SS, et al. Unveiling the hidden interactome of CRBN molecular glues. Nat Commun. 2025;16(1):6831.","journal-title":"Nat Commun"},{"issue":"1","key":"2320_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2320_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1042\/EBC20170041","volume":"61","author":"SJ Hughes","year":"2017","unstructured":"Hughes SJ, Ciulli A. Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders. Essays Biochem. 2017;61(5):505\u201316.","journal-title":"Essays Biochem"},{"issue":"1","key":"2320_CR22","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41467-017-00954-1","volume":"8","author":"C Maniaci","year":"2017","unstructured":"Maniaci C, Hughes SJ, Testa A, Chen W, Lamont DJ, Rocha S, et al. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation. Nat Commun. 2017;8(1):830.","journal-title":"Nat Commun"},{"issue":"22","key":"2320_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202400326","volume":"19","author":"J Yim","year":"2024","unstructured":"Yim J, Park J, Kim G, Lee HH, Chung JS, Jo A, et al. Conditional PROTAC: recent strategies for modulating targeted protein degradation. ChemMedChem. 2024;19(22):e202400326.","journal-title":"ChemMedChem"},{"key":"2320_CR24","doi-asserted-by":"crossref","unstructured":"Ram M, Fraser MR, Vieira dos Santos J, Tasakis R, Islam A, Abo-Donia JU, Parekh S, Lagana A. The genetic and molecular drivers of multiple myeloma: current insights, clinical implications, and the path forward. Pharmacogenomics Pers Med. 2024:;17:573-609.","DOI":"10.2147\/PGPM.S350238"},{"issue":"3","key":"2320_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181\u2013200.","journal-title":"Nat Rev Drug Discov"},{"issue":"6241","key":"2320_CR26","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348(6241):1376\u201381.","journal-title":"Science"},{"issue":"8","key":"2320_CR27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nchembio.1858","volume":"11","author":"DP Bondeson","year":"2015","unstructured":"Bondeson DP, Mares A, Smith IED, Ko E, Campos S, Miah AH, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015;11(8):611\u20137.","journal-title":"Nat Chem Biol"},{"issue":"2","key":"2320_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2017;16(2):101\u201314.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"2320_CR29","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nchembio.2329","volume":"13","author":"MS Gadd","year":"2017","unstructured":"Gadd MS, Testa A, Lucas X, Chan KH, Chen W, Lamont DJ, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017;13(5):514\u201321.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"2320_CR30","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","volume":"62","author":"J Hu","year":"2019","unstructured":"Hu J, Hu B, Wang M, Xu F, Miao B, Yang CY, et al. Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER). J Med Chem. 2019;62(3):1420\u201342.","journal-title":"J Med Chem"},{"issue":"6","key":"2320_CR31","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/anie.201507978","volume":"55","author":"M Toure","year":"2016","unstructured":"Toure M, Crews CM. Small-molecule PROTACS: new approaches to protein degradation. Angew Chem Int Ed. 2016;55(6):1966\u201373.","journal-title":"Angew Chem Int Ed"},{"issue":"8","key":"2320_CR32","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","volume":"10","author":"M Zengerle","year":"2015","unstructured":"Zengerle M, Chan KH, Ciulli A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem Biol. 2015;10(8):1770\u20137.","journal-title":"ACS Chem Biol"},{"issue":"1","key":"2320_CR33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","volume":"181","author":"GM Burslem","year":"2020","unstructured":"Burslem GM, Crews CM. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell. 2020;181(1):102\u201314.","journal-title":"Cell"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02320-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02320-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02320-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T22:21:36Z","timestamp":1786918896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02320-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2320"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02320-w","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors read and approved the final manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"145"}}